Cantor Fitzgerald Analysts Lower Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of $0.15 per share for the year, down from their prior estimate of $0.24. Cantor Fitzgerald currently has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

Several other research firms have also recently weighed in on ACAD. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday. Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. Finally, StockNews.com lowered ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.00.

ACADIA Pharmaceuticals Stock Up 1.8 %

Shares of ACAD stock opened at $19.34 on Friday. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $25.20. The firm has a 50 day moving average price of $18.37 and a two-hundred day moving average price of $16.81. The company has a market capitalization of $3.22 billion, a PE ratio of 24.79 and a beta of 0.37.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning raised its position in ACADIA Pharmaceuticals by 71.4% in the third quarter. Creative Planning now owns 25,061 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 10,441 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in ACADIA Pharmaceuticals by 11.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 121,625 shares of the biopharmaceutical company’s stock valued at $1,871,000 after buying an additional 12,787 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in ACADIA Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 1,066 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in ACADIA Pharmaceuticals by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 31,903 shares of the biopharmaceutical company’s stock worth $491,000 after buying an additional 12,493 shares during the period. Finally, US Bancorp DE grew its holdings in ACADIA Pharmaceuticals by 2,084.0% during the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company’s stock worth $507,000 after acquiring an additional 31,426 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.